Regardless of dosing regimen, patients treated with ranibizumab had a 43% higher incidence of GA, which was a statistically significant increase compared with bevacizumab. The ranibizumab group had ...

Please provide your email address to receive an email when new articles are posted on . Retinal implants have a history of challenges, and questions remain about their utility. A bioengineered RPE ...

The randomised, controlled phase 2 clinical trials will evaluate the safety and efficacy of Eyecyte-RPE in a larger group of ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Eyestem Research Pvt Ltd, a biotechnology company developing advanced scalable cell therapy solutions for blindness caused by dry age-related macular degeneration, has received ...

Management of geographic atrophy (GA) has changed with the introduction of retinal therapies aimed at slowing disease ...

—Among patients diagnosed with intermediate-stage age-related macular degeneration, a fair number of eyes in a new analysis showed evidence of geographic atrophy (GA), a leading cause of blindness. It ...